Marinus Pharmaceuticals Inc (FRA:61Y)
€ 0.302 -0.002 (-0.66%) Market Cap: 17.09 Mil Enterprise Value: 30.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Marinus Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript

May 15, 2023 / 07:30PM GMT
Release Date Price: €7.95 (-4.79%)
Jason Butler
JMP Group LLC - Moderator

All right. So thank you again for joining us this afternoon at the JMP Securities Life Science Conference. Excited to have Marinus Pharmaceuticals join us right now. Marinus is a company focused on the commercialization and development of novel therapies for CNS diseases. The company has an approved drug for a rare orphan epilepsy indication, CDKL5 deficiency disorder and also developing its lead candidate, ganaxolone for additional epilepsy and neurological indications.

So excited to be joined by company's CFO and COO, Steve Pfanstiel, and Alex -- sorry. Aimetti, the company's Chief Scientific Officer. Sorry, Alex. Thanks for being here, guys. Really, Steve, turn it over to you for a quick 30-second overview of Marinus, and then we'll go from there.

Steve Pfanstiel
Marinus Pharmaceuticals, Inc. - CFO

Yeah, sure. Well, just start quickly. So we are now a commercial stage company. We launched our first product Q3 of last year. We have two full quarters of commercialization under our belt. But also very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot